Skip to main content
Erschienen in: Osteoporosis International 1/2020

18.11.2019 | Original Article

Proton pump inhibitors and fracture risk. The HUNT study, Norway

verfasst von: M. Hoff, E. Skovlund, S. Skurtveit, H.E. Meyer, A. Langhammer, A.J. Søgaard, U. Syversen, S. Forsmo, B. Abrahamsen, B. Schei

Erschienen in: Osteoporosis International | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Summary

Proton pump inhibitors (PPIs) have been linked to increased risk of fracture; the data have, however, been diverging. We did not find any increased risk of fractures among users of PPIs in a Norwegian population of 15,017 women and 13,241 men aged 50–85 years with detailed information about lifestyle and comorbidity.

Introduction

Proton pump inhibitors (PPIs) are widely prescribed and have been linked to increased risk of fracture.

Methods

We used data from the Nord-Trøndelag Health Study (HUNT3), The Fracture registry in Nord-Trøndelag, and the Norwegian Prescription Database, including 15,017 women and 13,241 men aged 50–85 years. The study population was followed from the date of participating in HUNT3 (2006–2008) until the date of first fracture (forearm or hip), death, or end of study (31 December 2012). The Cox proportional hazards model with time-dependent exposure to PPIs was applied, and each individual was considered as unexposed until the first prescriptions was filled. To be included, the prescription of PPIs should minimum be equivalent to 90 defined daily doses (DDD) in the period. Individuals were defined as exposed until 6 months after end of drug supply.

Results

The proportion of women and men using PPIs was 17.9% and 15.5%, respectively. During a median of 5.2 years follow-up, 266 women and 134 men had a first hip fracture and 662 women and 127 men, a first forearm fracture. The combined rate/1000 patient-years for forearm and hip fractures in women was 49.2 for users of PPIs compared with 64.1 among non-users; for men 18.6 and 19.8, respectively. The hazard ratios with 95% confidence interval for the first forearm or hip fracture among users of PPIs in the age-adjusted analysis were 0.82 (0.67–1.01) for women and 1.05 (0.72–1.52) for men. Adjusting for age, use of anti-osteoporotic drugs, and FRAX, the HR declined to 0.80 (0.65–0.98) in women and 1.00 (0.69–1.45) in men.

Conclusions

Use of PPIs was not associated with an increased risk of fractures.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Yang YX, Lewis JD, Epstein S, Metz DC (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296:2947–2953PubMed Yang YX, Lewis JD, Epstein S, Metz DC (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296:2947–2953PubMed
3.
Zurück zum Zitat Vestergaard P, Rejnmark L, Mosekilde L (2006) Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 79:76–83PubMed Vestergaard P, Rejnmark L, Mosekilde L (2006) Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 79:76–83PubMed
5.
Zurück zum Zitat Poly TN, Islam MM, Yang HC, Wu CC, Li YJ (2019) Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 30:103–114 Poly TN, Islam MM, Yang HC, Wu CC, Li YJ (2019) Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 30:103–114
6.
Zurück zum Zitat Zhou B, Huang Y, Li H, Sun W, Liu J (2016) Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 27:339–347 Zhou B, Huang Y, Li H, Sun W, Liu J (2016) Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 27:339–347
7.
Zurück zum Zitat Cui GL, Syversen U, Zhao CM, Chen D, Waldum HL (2001) Long-term omeprazole treatment suppresses body weight gain and bone mineralization in young male rats. Scandinavian journal of gastroenterology 36:1011–1015PubMed Cui GL, Syversen U, Zhao CM, Chen D, Waldum HL (2001) Long-term omeprazole treatment suppresses body weight gain and bone mineralization in young male rats. Scandinavian journal of gastroenterology 36:1011–1015PubMed
8.
Zurück zum Zitat Fossmark R, Stunes AK, Petzold C, Waldum HL, Rubert M, Lian AM, Reseland JE, Syversen U (2012) Decreased bone mineral density and reduced bone quality in H(+)/K(+) ATPase beta-subunit deficient mice. J Cell Biochem 113:141–147PubMed Fossmark R, Stunes AK, Petzold C, Waldum HL, Rubert M, Lian AM, Reseland JE, Syversen U (2012) Decreased bone mineral density and reduced bone quality in H(+)/K(+) ATPase beta-subunit deficient mice. J Cell Biochem 113:141–147PubMed
9.
Zurück zum Zitat Ozdil K, Kahraman R, Sahin A, Calhan T, Gozden EH, Akyuz U, Erer B, Sokmen MH (2013) Bone density in proton pump inhibitors users: a prospective study. Rheumatol Int 33:2255–2260PubMed Ozdil K, Kahraman R, Sahin A, Calhan T, Gozden EH, Akyuz U, Erer B, Sokmen MH (2013) Bone density in proton pump inhibitors users: a prospective study. Rheumatol Int 33:2255–2260PubMed
10.
Zurück zum Zitat Bahtiri E, Islami H, Hoxha R, Qorraj-Bytyqi H, Rexhepi S, Hoti K, Thaci K, Thaci S, Karakulak C (2016) Esomeprazole use is independently associated with significant reduction of BMD: 1-year prospective comparative safety study of four proton pump inhibitors. Journal of bone and mineral metabolism 34:571–579PubMed Bahtiri E, Islami H, Hoxha R, Qorraj-Bytyqi H, Rexhepi S, Hoti K, Thaci K, Thaci S, Karakulak C (2016) Esomeprazole use is independently associated with significant reduction of BMD: 1-year prospective comparative safety study of four proton pump inhibitors. Journal of bone and mineral metabolism 34:571–579PubMed
11.
Zurück zum Zitat Targownik LE, Lix LM, Leung S, Leslie WD (2010) Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 138:896–904PubMed Targownik LE, Lix LM, Leung S, Leslie WD (2010) Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 138:896–904PubMed
12.
Zurück zum Zitat Targownik LE, Leslie WD, Davison KS et al (2012) The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol 107:1361–1369PubMedPubMedCentral Targownik LE, Leslie WD, Davison KS et al (2012) The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol 107:1361–1369PubMedPubMedCentral
13.
Zurück zum Zitat Shin YH, Gong HS, Baek GH (2019) Lower trabecular bone score is associated with the use of proton pump inhibitors. Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 22:236–242 Shin YH, Gong HS, Baek GH (2019) Lower trabecular bone score is associated with the use of proton pump inhibitors. Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 22:236–242
14.
Zurück zum Zitat Targownik LE, Goertzen AL, Luo Y, Leslie WD (2017) Long-term proton pump inhibitor use is not associated with changes in bone strength and structure. Am J Gastroenterol 112:95–101PubMed Targownik LE, Goertzen AL, Luo Y, Leslie WD (2017) Long-term proton pump inhibitor use is not associated with changes in bone strength and structure. Am J Gastroenterol 112:95–101PubMed
15.
Zurück zum Zitat Lewis JR, Barre D, Zhu K, Ivey KL, Lim EM, Hughes J, Prince RL (2014) Long-term proton pump inhibitor therapy and falls and fractures in elderly women: a prospective cohort study. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 29:2489–2497 Lewis JR, Barre D, Zhu K, Ivey KL, Lim EM, Hughes J, Prince RL (2014) Long-term proton pump inhibitor therapy and falls and fractures in elderly women: a prospective cohort study. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 29:2489–2497
16.
Zurück zum Zitat O'Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ (2005) Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 118:778–781PubMed O'Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ (2005) Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 118:778–781PubMed
17.
Zurück zum Zitat Nehra AK, Alexander JA, Loftus CG, Nehra V (2018) Proton pump inhibitors: review of emerging concerns. Mayo Clin Proc 93:240–246PubMed Nehra AK, Alexander JA, Loftus CG, Nehra V (2018) Proton pump inhibitors: review of emerging concerns. Mayo Clin Proc 93:240–246PubMed
18.
Zurück zum Zitat Corsonello A, Lattanzio F, Bustacchini S, Garasto S, Cozza A, Schepisi R, Lenci F, Luciani F, Maggio MG, Ticinesi A, Butto V, Tagliaferri S, Corica F (2018) Adverse events of proton pump inhibitors: potential mechanisms. Curr Drug Metab 19:142–154PubMed Corsonello A, Lattanzio F, Bustacchini S, Garasto S, Cozza A, Schepisi R, Lenci F, Luciani F, Maggio MG, Ticinesi A, Butto V, Tagliaferri S, Corica F (2018) Adverse events of proton pump inhibitors: potential mechanisms. Curr Drug Metab 19:142–154PubMed
19.
Zurück zum Zitat Wright MJ, Sullivan RR, Gaffney-Stomberg E, Caseria DM, O'Brien KO, Proctor DD, Simpson CA, Kerstetter JE, Insogna KL (2010) Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 25:2205–2211 Wright MJ, Sullivan RR, Gaffney-Stomberg E, Caseria DM, O'Brien KO, Proctor DD, Simpson CA, Kerstetter JE, Insogna KL (2010) Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 25:2205–2211
20.
Zurück zum Zitat Aasarod KM, Ramezanzadehkoldeh M, Shabestari M et al (2016) Skeletal effects of a gastrin receptor antagonist in H+/K+ATPase beta subunit KO mice. J Endocrinol 230:251–262PubMed Aasarod KM, Ramezanzadehkoldeh M, Shabestari M et al (2016) Skeletal effects of a gastrin receptor antagonist in H+/K+ATPase beta subunit KO mice. J Endocrinol 230:251–262PubMed
21.
Zurück zum Zitat Cundy T, Dissanayake A (2008) Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol 69:338–341 Cundy T, Dissanayake A (2008) Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol 69:338–341
22.
Zurück zum Zitat Famularo G, Gasbarrone L, Minisola G (2013) Hypomagnesemia and proton-pump inhibitors. Expert Opin Drug Saf 12:709–716PubMed Famularo G, Gasbarrone L, Minisola G (2013) Hypomagnesemia and proton-pump inhibitors. Expert Opin Drug Saf 12:709–716PubMed
23.
Zurück zum Zitat Kunutsor SK, Whitehouse MR, Blom AW, Laukkanen JA (2017) Low serum magnesium levels are associated with increased risk of fractures: a long-term prospective cohort study. Eur J Epidemiol 32:593–603PubMedPubMedCentral Kunutsor SK, Whitehouse MR, Blom AW, Laukkanen JA (2017) Low serum magnesium levels are associated with increased risk of fractures: a long-term prospective cohort study. Eur J Epidemiol 32:593–603PubMedPubMedCentral
24.
Zurück zum Zitat Prause M, Seeliger C, Unger M, Rosado Balmayor E, van Griensven M, Haug AT (2015) Pantoprazole decreases cell viability and function of human osteoclasts in vitro. Mediat Inflamm 2015:413097 Prause M, Seeliger C, Unger M, Rosado Balmayor E, van Griensven M, Haug AT (2015) Pantoprazole decreases cell viability and function of human osteoclasts in vitro. Mediat Inflamm 2015:413097
25.
Zurück zum Zitat Costa-Rodrigues J, Reis S, Teixeira S, Lopes S, Fernandes MH (2013) Dose-dependent inhibitory effects of proton pump inhibitors on human osteoclastic and osteoblastic cell activity. FEBS J 280:5052–5064PubMed Costa-Rodrigues J, Reis S, Teixeira S, Lopes S, Fernandes MH (2013) Dose-dependent inhibitory effects of proton pump inhibitors on human osteoclastic and osteoblastic cell activity. FEBS J 280:5052–5064PubMed
26.
Zurück zum Zitat Jo Y, Park E, Ahn SB, Jo YK, Son B, Kim SH, Park YS, Kim HJ (2015) A proton pump inhibitor's effect on bone metabolism mediated by osteoclast action in old age: a prospective randomized study. Gut and liver 9:607–614PubMed Jo Y, Park E, Ahn SB, Jo YK, Son B, Kim SH, Park YS, Kim HJ (2015) A proton pump inhibitor's effect on bone metabolism mediated by osteoclast action in old age: a prospective randomized study. Gut and liver 9:607–614PubMed
27.
Zurück zum Zitat Prause M, Seeliger C, Unger M, van Griensven M, Haug AT (2014) Pantoprazole increases cell viability and function of primary human osteoblasts in vitro. Injury 45:1156–1164PubMed Prause M, Seeliger C, Unger M, van Griensven M, Haug AT (2014) Pantoprazole increases cell viability and function of primary human osteoblasts in vitro. Injury 45:1156–1164PubMed
28.
Zurück zum Zitat Joo MK, Park JJ, Lee BJ, Kim JH, Yeon JE, Kim JS, Byun KS, Bak YT (2013) The effect of a proton pump inhibitor on bone metabolism in ovariectomized rats. Molecular medicine reports 7:1267–1272PubMed Joo MK, Park JJ, Lee BJ, Kim JH, Yeon JE, Kim JS, Byun KS, Bak YT (2013) The effect of a proton pump inhibitor on bone metabolism in ovariectomized rats. Molecular medicine reports 7:1267–1272PubMed
29.
Zurück zum Zitat Leontiadis GI, Moayyedi P (2014) Proton pump inhibitors and risk of bone fractures. Current treatment options in gastroenterology 12:414–423PubMed Leontiadis GI, Moayyedi P (2014) Proton pump inhibitors and risk of bone fractures. Current treatment options in gastroenterology 12:414–423PubMed
30.
Zurück zum Zitat Targownik LE (2018) Editorial: Non-breaking news! High-dose PPIs likely do not cause fractures. Aliment Pharmacol Ther 47:137PubMed Targownik LE (2018) Editorial: Non-breaking news! High-dose PPIs likely do not cause fractures. Aliment Pharmacol Ther 47:137PubMed
31.
Zurück zum Zitat Cea Soriano L, Ruigomez A, Johansson S, Garcia Rodriguez LA (2014) Study of the association between hip fracture and acid-suppressive drug use in a UK primary care setting. Pharmacotherapy 34:570–581PubMed Cea Soriano L, Ruigomez A, Johansson S, Garcia Rodriguez LA (2014) Study of the association between hip fracture and acid-suppressive drug use in a UK primary care setting. Pharmacotherapy 34:570–581PubMed
32.
Zurück zum Zitat Moayyedi P, Leontiadis GI (2012) The risks of PPI therapy. Nat Rev Gastroenterol Hepatol 9:132–139PubMed Moayyedi P, Leontiadis GI (2012) The risks of PPI therapy. Nat Rev Gastroenterol Hepatol 9:132–139PubMed
33.
Zurück zum Zitat Furu K (2008) Establishment of the nationwide Norwegian Prescription Database (NorPD)–new opportunities for research in pharmacoepidemiology in Norway. Norsk Epidemiologi:129–136 Furu K (2008) Establishment of the nationwide Norwegian Prescription Database (NorPD)–new opportunities for research in pharmacoepidemiology in Norway. Norsk Epidemiologi:129–136
34.
Zurück zum Zitat Krokstad S, Langhammer A, Hveem K, Holmen T, Midthjell K, Stene T, Bratberg G, Heggland J, Holmen J (2012) Cohort profile: the HUNT study, Norway. Int J Epidemiol Krokstad S, Langhammer A, Hveem K, Holmen T, Midthjell K, Stene T, Bratberg G, Heggland J, Holmen J (2012) Cohort profile: the HUNT study, Norway. Int J Epidemiol
35.
Zurück zum Zitat Kanis JA, Oden A, Johansson H, Borgstrom F, Strom O, McCloskey E (2009) FRAX and its applications to clinical practice. Bone 44:734–743PubMed Kanis JA, Oden A, Johansson H, Borgstrom F, Strom O, McCloskey E (2009) FRAX and its applications to clinical practice. Bone 44:734–743PubMed
36.
Zurück zum Zitat Hoff M, Meyer HE, Skurtveit S, Langhammer A, Sogaard AJ, Syversen U, Dhainaut A, Skovlund E, Abrahamsen B, Schei B (2017) Validation of FRAX and the impact of self-reported falls among elderly in a general population: the HUNT study, Norway. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA Hoff M, Meyer HE, Skurtveit S, Langhammer A, Sogaard AJ, Syversen U, Dhainaut A, Skovlund E, Abrahamsen B, Schei B (2017) Validation of FRAX and the impact of self-reported falls among elderly in a general population: the HUNT study, Norway. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
37.
Zurück zum Zitat Gronskag AB, Forsmo S, Romundstad P, Langhammer A, Schei B (2010) Incidence and seasonal variation in hip fracture incidence among elderly women in Norway. The HUNT study. Bone 46:1294–1298PubMed Gronskag AB, Forsmo S, Romundstad P, Langhammer A, Schei B (2010) Incidence and seasonal variation in hip fracture incidence among elderly women in Norway. The HUNT study. Bone 46:1294–1298PubMed
38.
Zurück zum Zitat Hoff M, Skurtveit S, Meyer HE, Langhammer A, Sogaard AJ, Syversen U, Abrahamsen B, Schei B (2015) Use of anti-osteoporotic drugs in central Norway after a forearm fracture. Archives of osteoporosis 10:235PubMed Hoff M, Skurtveit S, Meyer HE, Langhammer A, Sogaard AJ, Syversen U, Abrahamsen B, Schei B (2015) Use of anti-osteoporotic drugs in central Norway after a forearm fracture. Archives of osteoporosis 10:235PubMed
39.
Zurück zum Zitat Blum MR, Bauer DC, Collet TH, Fink HA, Cappola AR, da Costa BR, Wirth CD, Peeters RP, Åsvold BO, den Elzen W, Luben RN, Imaizumi M, Bremner AP, Gogakos A, Eastell R, Kearney PM, Strotmeyer ES, Wallace ER, Hoff M, Ceresini G, Rivadeneira F, Uitterlinden AG, Stott DJ, Westendorp RG, Khaw KT, Langhammer A, Ferrucci L, Gussekloo J, Williams GR, Walsh JP, Jüni P, Aujesky D, Rodondi N, Thyroid Studies Collaboration (2015) Subclinical thyroid dysfunction and fracture risk: a meta-analysis. JAMA 313:2055–2065PubMedPubMedCentral Blum MR, Bauer DC, Collet TH, Fink HA, Cappola AR, da Costa BR, Wirth CD, Peeters RP, Åsvold BO, den Elzen W, Luben RN, Imaizumi M, Bremner AP, Gogakos A, Eastell R, Kearney PM, Strotmeyer ES, Wallace ER, Hoff M, Ceresini G, Rivadeneira F, Uitterlinden AG, Stott DJ, Westendorp RG, Khaw KT, Langhammer A, Ferrucci L, Gussekloo J, Williams GR, Walsh JP, Jüni P, Aujesky D, Rodondi N, Thyroid Studies Collaboration (2015) Subclinical thyroid dysfunction and fracture risk: a meta-analysis. JAMA 313:2055–2065PubMedPubMedCentral
41.
Zurück zum Zitat Vollset SE (1993) Confidence intervals for a binomial proportion. Stat Med 12:809–824PubMed Vollset SE (1993) Confidence intervals for a binomial proportion. Stat Med 12:809–824PubMed
42.
Zurück zum Zitat van der Hoorn MMC, Tett SE, de Vries OJ, Dobson AJ, Peeters G (2015) The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study. Bone 81:675–682PubMed van der Hoorn MMC, Tett SE, de Vries OJ, Dobson AJ, Peeters G (2015) The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study. Bone 81:675–682PubMed
43.
Zurück zum Zitat Vestergaard P, Steinberg TH, Schwarz P, Jorgensen NR (2012) Use of the oral platelet inhibitors dipyridamole and acetylsalicylic acid is associated with increased risk of fracture. Int J Cardiol 160:36–40PubMed Vestergaard P, Steinberg TH, Schwarz P, Jorgensen NR (2012) Use of the oral platelet inhibitors dipyridamole and acetylsalicylic acid is associated with increased risk of fracture. Int J Cardiol 160:36–40PubMed
44.
Zurück zum Zitat Dadwal G, Schulte-Huxel T, Kolb G (2019) Effect of antithrombotic drugs on bone health. Zeitschrift fur Gerontologie und Geriatrie Dadwal G, Schulte-Huxel T, Kolb G (2019) Effect of antithrombotic drugs on bone health. Zeitschrift fur Gerontologie und Geriatrie
45.
46.
Zurück zum Zitat Carbone LD, Tylavsky FA, Cauley JA, Harris TB, Lang TF, Bauer DC, Barrow KD, Kritchevsky SB (2003) Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: impact of cyclooxygenase selectivity. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 18:1795–1802 Carbone LD, Tylavsky FA, Cauley JA, Harris TB, Lang TF, Bauer DC, Barrow KD, Kritchevsky SB (2003) Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: impact of cyclooxygenase selectivity. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 18:1795–1802
47.
Zurück zum Zitat Bonten TN, de Mutsert R, Rosendaal FR, Jukema JW, van der Bom JG, de Jongh RT, den Heijer M (2017) Chronic use of low-dose aspirin is not associated with lower bone mineral density in the general population. Int J Cardiol 244:298–302PubMed Bonten TN, de Mutsert R, Rosendaal FR, Jukema JW, van der Bom JG, de Jongh RT, den Heijer M (2017) Chronic use of low-dose aspirin is not associated with lower bone mineral density in the general population. Int J Cardiol 244:298–302PubMed
48.
Zurück zum Zitat Levesque LE, Hanley JA, Kezouh A, Suissa S (2010) Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. Bmj 340:b5087PubMed Levesque LE, Hanley JA, Kezouh A, Suissa S (2010) Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. Bmj 340:b5087PubMed
Metadaten
Titel
Proton pump inhibitors and fracture risk. The HUNT study, Norway
verfasst von
M. Hoff
E. Skovlund
S. Skurtveit
H.E. Meyer
A. Langhammer
A.J. Søgaard
U. Syversen
S. Forsmo
B. Abrahamsen
B. Schei
Publikationsdatum
18.11.2019
Verlag
Springer London
Erschienen in
Osteoporosis International / Ausgabe 1/2020
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-019-05206-0

Weitere Artikel der Ausgabe 1/2020

Osteoporosis International 1/2020 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.